The differences indicate that A/Vietnam/14011801/2014 is a novel reassortant virus between clades 2.3.2.1a and 2.3.2.1c, between clades 1.1.2 and 2.3.2.1c, or both (Figure). This novel reassortant virus has not been reported in poultry in Vietnam, although novel reassortants between clade 1.1.2 and clade 2.3.2.1a viruses have been detected in Vietnam since 2013 (i.e., A/Vietnam/VP13-28H/2013, GISAID accession nos. EPI624927–EPI624934; and A/Vietnam/14012902/2014) (6). These novel reassortment viruses were first identified in human, animal, and environmental samples in Cambodia in 2013 (5). Other novel gene reassortments in clade 2.3.2.1 viruses have been previously reported (10), and new clade 2.3.4.4 viruses have been observed in Vietnam since 2014.

As multiple clade viruses co-circulate, reassortment events occur frequently in Vietnam. Continuous surveillance of avian influenza A(H5N1) viruses, not only in humans but also in poultry and wild birds, is needed for infection control measures during epidemics of these viruses.

This study was partially supported by Grants-in-Aid for Emerging and Reemerging Infectious Diseases from the Ministry of Health, Labour and Welfare, Japan.

References

Address for correspondence: Tsutomu Kageyama, Influenza Virus Research Center, National Institute of Infectious Diseases, 4-7-1 Gakuen, Musashimurayama-shi, Tokyo 208-0011, Japan; email: tkage@nih.go.jp

**Mycobacterium arupense as an Emerging Cause of Tenosynovitis**

Fiorella Krapp Lopez, Madeline Miley, Babafemi Taiwo

Author affiliations: Northwestern University, Chicago, Illinois, USA (F. Krapp Lopez, B. Taiwo); Northwestern Memorial Hospital, Chicago (M. Miley)

DOI: http://dx.doi.org/10.3201/eid2203.151749

To the Editor: *Mycobacterium arupense* was identified as a novel species within the *M. terrae* complex with close similarity to *M. nonchromogenicum* (I). Since then, 8 cases describing clinically notable disease have been published (2–8), including 5 cases of tenosynovitis. We report *M. arupense* tenosynovitis in an immunocompromised person who received the selective interleukin (IL) 1β-inhibitor canakinumab.

In July 2014, a 62-year-old man sought treatment at the emergency department, Northwestern Memorial Hospital (Chicago, Illinois, USA), after 1 week of pain and swelling in the right hand. During the previous 5 years, he had received multiple immunomodulatory drugs for treatment of natural killer cell deficiency, hyper–IL-6 syndrome, recurrent polychondritis, and Sweet syndrome. His medications were prednisone (42.5 mg/d), intravenous canakinumab.

His first symptom was a tender red nodule on the right palm that increased in size and became extremely tender over the following week (Figure, panels A, B). He did not recall any trauma and denied fever or chills. No improvement was seen after he received oral linezolid for 5 days.

M. arupense was isolated from the primary lesion on the right palm, and other swab cultures from the surrounding skin and synovial fluid were negative. Subsequent cultures of the primary lesion on the right palm were positive for *M. arupense* and *Mycobacterium terrae* complex.

Since then, 8 cases describing clinically notable disease have been published (2–8), including 5 cases of tenosynovitis. We report *M. arupense* tenosynovitis in an immunocompromised person who received the selective interleukin (IL) 1β-inhibitor canakinumab.
skin punch biopsy specimen showed a neutrophilic interstitial infiltrate with no granulomas; results of microbiological stains, including acid-fast bacilli, were negative. His prednisone dosage was increased to 60 mg/d for suspected Sweet syndrome and, subsequently, to 80 mg/d when no improvement was observed after 2 weeks. A second dose of canakinumab was administered 8 weeks after the first. Shortly after, he was readmitted to the hospital with progression of edema and pain and signs consistent with carpal tunnel syndrome and trigger finger syndrome of the right index finger. Magnetic resonance imaging showed extensive tenosynovitis of the carpal tunnel flexor tendons and no bone erosions. Surgical release and tenosynovectomy of the carpal tunnel was performed; pathologic features demonstrated chronic inflammation of the synovium and absence of granulomas. Results of microbiological stains were negative.

*M. arupense* grew on Löwenstein-Jensen culture from the skin biopsy specimen after 35 days and from a synovium specimen after 22 days. No growth was observed on liquid culture media. Empiric treatment was started immediately after the first positive culture: clarithromycin (500 mg 2×/d), ethambutol (1,200 mg/d), and rifabutin (300 mg/d). Prednisone was decreased to 45 mg/d, and canakinumab was discontinued. Susceptibility testing confirmed the *M. arupense* strain’s susceptibility to clarithromycin, ethambutol, and rifabutin (MICs <4.0, <1.25, and <0.12, respectively); intermediate resistance to rifampin and amikacin (MIC 4.0); and resistance to moxifloxacin and ciprofloxacin (MIC >4.0) and to kanamycin (MIC >8.0). Clinical improvement occurred after 8 weeks of treatment; the condition resolved after 6 months (Figure, panels C, D). Treatment was continued for 12 months.

Five other cases of *M. arupense* tenosynovitis have been reported (2,4,5,7,8); all patients were immunocompetent or minimally immunocompromised (i.e., diabetes mellitus) (online Technical Appendix, http://wwwnc.cdc.gov/EID/article/22/3/15-1749-Techapp1.pdf). The hand was the site of infection in all cases, and 4 of 5 patients reported prior trauma to the affected area, which suggests that inoculation was the infection mechanism. In the case we describe, the disease appeared to progress much faster than in the immunocompetent patients (weeks vs. months to years). Acid-fast bacilli stain was negative in all of the cases where it was performed (2,7,8; this study), and growth on solid Löwenstein-Jensen stain or Middlebrook media was seen after a prolonged incubation time, ranging from 27 days to 2 months. Liquid culture media appears to be unreliable for the growth of *M. arupense* (8; this study).

A combination of tenosynovectomy and prolonged antimycobacterial treatment, guided by in vitro strain susceptibility, was used in all the reported cases; a positive outcome was achieved in 6–14 months. The strain susceptibility results we found are comparable with those in the previous cases, showing consistent susceptibility to clarithromycin, ethambutol, and rifabutin; variable susceptibility to linezolid, streptomycin, and amikacin; and resistance to rifampin and quinolones.
Two cases of *M. arupense* infection have been reported in immunosuppressed persons, both in HIV/AIDS patients (manifesting as pulmonary infection in 1 patient and disseminated disease in the other) (6). In our study, the immunocompromised patient with *M. arupense* tenosynovitis received canakinumab, a relatively new biologic agent with a prolonged selective IL-1 β-blockade. Even though the contribution of canakinumab in this case is confounded by concomitant immune deficiencies (natural killer cell deficiency, high-dose corticosteroids), the temporal association between initiation of canakinumab and the onset of symptoms raises concern of a possible association. Animal studies have shown that IL-1 plays a key role in host resistance to mycobacterial infections by regulating Th1/Th2 immune responses and inducing granuloma formation (9). Clinical trials and systematic reviews assessing the safety of IL-1 inhibitors, including anakinra, rilonacept, and canakinumab, have not shown that these drugs lead to an increased risk of tuberculosis or other mycobacterial infections (10). Nonetheless, our report provides increased evidence that *M. arupense* is an emerging cause of tenosynovitis and that it is potentially associated with immunosuppression.

References


Address for correspondence: Fiorella Krapp Lopez, Division of Infectious Diseases, Department of Medicine, Northwestern University, 645 N Michigan Ave, Ste 900, Chicago, IL 60611, USA; email: fiorella.krapp@northwestern.edu

---

**Candida haemulonii** Complex Species, Brazil, January 2010–March 2015

João Nobrega de Almeida, Jr., João Guilherme Pontes Lima Assy, Anna S. Levin, Gilda M.B. Del Negro, Mauro C. Giudice, Marcela Pullice Tringoni, Danilo Yamamoto Thomaz, Adriana Lopes Motta, Edson Abdala, Lígia Camara Pierroti, Tania Strabelli, Ana Lucia Munhoz, Flávia Rossi, Gil Benard

Author affiliation: Universidade de São Paulo, São Paulo, Brazil

DOI: http://dx.doi.org/10.3201/eid2203.151610

To the Editor: The epidemiology of yeast infections is evolving, and species in the *Candida haemulonii* complex have been identified as a cause of candidiasis (1). In 2012, *C. haemulonii* complex was reclassified as 2 species and 1 variety: *C. haemulonii* (former group I), *C. dubosshaemulonii* (former group II) and *C. haemulonii* var. *vulnera* (1).

Despite the growing knowledge about the biology and clinical relevance of these pathogens, species-specific data comparing clinical and microbiological aspects are lacking. We describe the clinical and microbiological characteristics of patients from 5 hospitals in São Paulo, Brazil, whose cultures were positive for the *C. haemulonii* complex species.

During January 2010–March 2015, samples from case-patients in 5 hospitals affiliated with the University of São Paulo were cultured; samples positive for *C. haemulonii* were further analyzed. Clinical and epidemiologic data were retrospectively collected. Species identification of the first isolate from each patient was made by sequencing the internal transcribed spacer region of the rRNA gene (2). Sequence similarity searches were done by using BLAST (http://www.ncbi.nlm.nih.gov/BLAST). Antifungal susceptibility testing was performed by using the Clinical
Mycobacterium arupense as an Emerging Cause of Tenosynovitis

Technical Appendix

Technical Appendix Table 1. Patient clinical characteristics of case-patients with Mycobacterium arupense tenosynovitis* in published reports

<table>
<thead>
<tr>
<th>Report</th>
<th>Year</th>
<th>Country</th>
<th>Sex, age, y</th>
<th>Coexisting condition</th>
<th>Presentation</th>
<th>Initial event</th>
<th>Risk for progression</th>
<th>Symptom duration, wk†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tsai et al. (1)</td>
<td>2008</td>
<td>Taiwan</td>
<td>F, 54</td>
<td>Diabetes mellitus</td>
<td>TS/hand</td>
<td>Blunt trauma</td>
<td>Corticosteroid injection</td>
<td>28</td>
</tr>
<tr>
<td>Senda et al. (2)</td>
<td>2011</td>
<td>Japan</td>
<td>M, 68</td>
<td>Hypertension</td>
<td>TS/hand</td>
<td>None</td>
<td>Corticosteroid injection</td>
<td>20</td>
</tr>
<tr>
<td>Legout et al. (3)</td>
<td>2012</td>
<td>France</td>
<td>M, 35</td>
<td>None</td>
<td>TS and OM/wrist</td>
<td>Penetrating trauma (glass)</td>
<td>Corticosteroid injection</td>
<td>68</td>
</tr>
<tr>
<td>Lee et al. (4)</td>
<td>2014</td>
<td>North Korea</td>
<td>F, 56</td>
<td>Hypertension, resected pituitary adenoma. Receiving low-dose prednisolone.</td>
<td>TS/hand</td>
<td>Penetrating trauma (by crab)</td>
<td>Corticosteroid injection</td>
<td>44</td>
</tr>
<tr>
<td>Beam et al. (5)</td>
<td>2014</td>
<td>USA</td>
<td>M, 58</td>
<td>None</td>
<td>TS/hand</td>
<td>Remote blunt trauma</td>
<td>Systemic corticosteroids, methotrexate, adalimumab</td>
<td>100</td>
</tr>
<tr>
<td>This report</td>
<td>2015</td>
<td>USA</td>
<td>M, 62</td>
<td>NK cell deficiency, hyper IL-6 syndrome, recurrent polychondritis, Sweet syndrome. Receiving high-dose prednisone and canakinumab.</td>
<td>TS/hand and wrist</td>
<td>None</td>
<td>Increasing dose of systemic corticosteroids</td>
<td>6</td>
</tr>
</tbody>
</table>

*TS, tenosynovitis; OM, osteomyelitis; NK, natural killer; IL, interleukin.
†Time reported from initial symptoms to diagnosis.

Technical Appendix Table 2. Microbiological and treatment characteristics of case-patients with Mycobacterium arupense tenosynovitis in published reports *

<table>
<thead>
<tr>
<th>Case</th>
<th>Pathology</th>
<th>Culture</th>
<th>Identification method</th>
<th>Susceptibility</th>
<th>Resistance</th>
<th>Treatment</th>
<th>Treatment duration, mo</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tsai et al. (1)</td>
<td>Granulomas+, AFB–</td>
<td>L-J positive at 60 d</td>
<td>16S rRNA, hsp65 and rpoB</td>
<td>NR</td>
<td>NR</td>
<td>Synovectomy, clarithromycin, ethambutol, rifabutin, moxifloxacin, ciprofloxacin</td>
<td>6</td>
<td>Resolved</td>
</tr>
<tr>
<td>Senda et al. (2)</td>
<td>Granulomas+, AFB NR</td>
<td>L-J negative</td>
<td>DNA-DNA hybridization</td>
<td>NA</td>
<td>NA</td>
<td>Synovectomy, ethambutol, rifampin</td>
<td>14</td>
<td>Resolved</td>
</tr>
<tr>
<td>Legout et al. (3)</td>
<td>Granulomas+, AFB NR</td>
<td>L-J positive</td>
<td>16S rRNA and hsp65</td>
<td>NR</td>
<td>NR</td>
<td>Synovectomy and arthrodectomy. Clarithromycin, ciprofloxacin, amikacin (1 mo), ethambutol (2 mo)</td>
<td>12</td>
<td>Resolved</td>
</tr>
<tr>
<td>Lee et al. (4)</td>
<td>Granulomas+, AFB–</td>
<td>L-J positive at 27 d</td>
<td>16S rRNA and hsp65</td>
<td>Clarithromycin, ethambutol, linezolid</td>
<td>Ciprofloxacin, moxifloxacin, rifampin</td>
<td>Synovectomy, clarithromycin, ethambutol, rifampin</td>
<td>NR</td>
<td>Resolved</td>
</tr>
<tr>
<td>Case</td>
<td>Pathology</td>
<td>Culture</td>
<td>Identification method</td>
<td>Susceptibility</td>
<td>Resistance</td>
<td>Treatment</td>
<td>Treatment duration, mo</td>
<td>Outcome</td>
</tr>
<tr>
<td>----------------------</td>
<td>-----------------</td>
<td>--------------------------</td>
<td>-----------------------</td>
<td>-------------------------</td>
<td>-----------------------------</td>
<td>-----------</td>
<td>------------------------</td>
<td>---------</td>
</tr>
<tr>
<td>Beam et al. (5)</td>
<td>Granulomas– , AFB–</td>
<td>MGIT negative L-J positive at 33 d</td>
<td>16S rRNA</td>
<td>Clarithromycin, ethambutol, rifabutin</td>
<td>amikacin, TMP/SMX, Ciprofloxacin, moxifloxacin, rifampin, amikacin, TMP/SMX, linezolid</td>
<td>Synovectomy. clarithromycin, ethambutol, rifabutin</td>
<td>6, ongoing</td>
<td>Improved</td>
</tr>
<tr>
<td>This study</td>
<td>Granulomas– , AFB–</td>
<td>MGIT negative L-J positive at 35 d</td>
<td>16S rRNA</td>
<td>Synovectomy. clarithromycin, ethambutol, rifabutin</td>
<td>12</td>
<td>Resolved</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*AFB, acid-fast bacilli staining; L-J, Löwenstein-Jensen culture; MGIT, mycobacteria growth indicator tube; NR, not reported; NA, not applicable; TMP/SMX, trimethoprim/sulfamethoxazole.
†Time reported from initial symptoms to diagnosis.

References


